GSK's drug combo shown to cut risk of death by 42% in type of blood cancer
British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer, at or after first relapse compared to an existing treatment.
The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...
GSK’s cancer drug failed a confirmatory trial two years after an accelerated approval, but impressive new survival data could ...
GSK announces success of their drug Blenrep at reducing the risk of death in patients diagnosed with multiple myeloma.
Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...
GSK last month announced that Blenrep had succeeded in improving overall survival in the trial, called DREAMM-7. The detailed ...
London: GSK plc has announced that the National Medical Products Administration (NMPA) of China has accepted for review a new ...
Two years after pulling Blenrep from the market, GSK is positioning for a relaunch. This time, the company says it’s coming ...
Market analysts liked the news, with analysts for Cantor writing that this was a “best-case data update.” ...
GSK (GSK) announced that the National Medical Products Administration, NMPA, of China has accepted for review a new drug application, NDA, for ...
Hosted on MSN2d
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPDGSK plc GSK announced that the FDA has accepted its regulatory filing, seeking the approval of a new indication for Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD) treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback